Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT05600257	The Effect of Digital Breast Tomosynthesis in Breast Cancer Long-term Survival: a Single Institution Study		Completed	No Results Available	Breast Cancer	Device: DBT|Device: DM	Overall survival rate	Kaohsiung Veterans General Hospital.	Female	23 Years to 89 Years   (Adult, Older Adult)		1517	Other	Observational	Observational Model: Cohort|Time Perspective: Retrospective	KSVGH22-CT11-01	September 1, 2011	August 31, 2021	August 31, 2021	October 31, 2022		November 4, 2022	Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan		https://ClinicalTrials.gov/show/NCT05600257
2	NCT03254875	Rehabilitation After Breast Cancer	REBECCA II	Completed	No Results Available	Breast Cancer	Behavioral: Individually tailored nurse navigation	Distress|Depression|Anxiety|Health related quality of life summary index|Breast cancer related quality of life summary index|Functional related quality of life summary index|Physical health related quality of life|Social health related quality of life|Emotional health related quality of life|Self-efficacy|Fear of recurrence|Pain in the breast surgery area (side of chest, armpit or arm)|Neuropathy in the breast surgery area (side of chest, armpit or arm)|Sleep quality|Cognitive function - Perceived cognitive impairments|Cognitive function- Perceived cognitive impairments|Cognitive function - Impact of Perceived cognitive impairments on quality of life|Cognitive function - Perceived cognitive abilities|Need for support|Health care costs|Acceptability	Danish Cancer Society|Rigshospitalet, Denmark|Copenhagen University Hospital at Herlev	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	309	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	REBECCA II	August 15, 2017	March 31, 2021	March 31, 2021	August 21, 2017		August 27, 2021	Rigshospitalet, Copenhagen, Denmark		https://ClinicalTrials.gov/show/NCT03254875
3	NCT03865654	Individualizing Surveillance Mammography for Older Breast Cancer Survivors		Completed	Has Results	Breast Cancer	Other: Communication Tool	Rate of Change in Intentions for Mammography in the Next Year|Rate of Satisfaction|Preferred Decision-making Role	Dana-Farber Cancer Institute|National Institutes of Health (NIH)|National Cancer Institute (NCI)	Female	75 Years and older   (Older Adult)	Not Applicable	45	Other|NIH	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	19-001|1R21CA227615-01A1	May 16, 2019	July 1, 2021	July 1, 2021	March 7, 2019	August 24, 2022	August 24, 2022	Dana-Farber Cancer Institute, Boston, Massachusetts, United States	"Study Protocol", https://clinicaltrials.gov/ProvidedDocs/54/NCT03865654/Prot_000.pdf|"Statistical Analysis Plan", https://clinicaltrials.gov/ProvidedDocs/54/NCT03865654/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT03865654
4	NCT03913936	Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot		Completed	No Results Available	Breast Cancer	Other: YES portal	Frequency of logging into the portal.|Time spent in the portal.|Time spent responding the survey.|Frequency of information downloads.|Participant-reported utility of the portal.|Participant-reported recommendations for improving the portal.	Dana-Farber Cancer Institute|Breast Cancer Research Foundation	Female	18 Years to 44 Years   (Adult)	Not Applicable	30	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	18-641	May 23, 2019	September 19, 2019	September 19, 2019	April 12, 2019		April 3, 2023	Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03913936
5	NCT05460702	Relationship Between Breast Cancer Subtypes and Immune Checkpoints		Completed	No Results Available	Breast Cancer	Diagnostic Test: Soluble immune checkpoints	Immune checkpoints	Istanbul Training and Research Hospital	Female	18 Years to 90 Years   (Adult, Older Adult)		60	Other	Observational	Observational Model: Case-Control|Time Perspective: Prospective	Breast immune checkpoint	May 1, 2022	December 1, 2022	December 15, 2022	July 15, 2022		February 16, 2023	Istanbul Training and Research Hospital, Istanbul, Turkey|Memorial Hizmet Hospital, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT05460702
6	NCT05797129	CEDM as a Screening Tool for Breast Cancer in Higher-risk Women: A Prospective Study		Completed	No Results Available	Breast Cancer	Device: CEDM	Total number of cases received and diagnosed with breast cancer (Number)|Total number of cases received and diagnosed as positive requiring a biopsy and MRI (Number)|True positive results obtained by the diagnostic method (Number)|True negative results obtained by the diagnostic method (Number)	Kaohsiung Veterans General Hospital.	Female	20 Years to 90 Years   (Adult, Older Adult)		351	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	VGHKS18-CT11-17	January 1, 2019	December 31, 2021	December 31, 2021	April 4, 2023		April 4, 2023	Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan		https://ClinicalTrials.gov/show/NCT05797129
7	NCT03375827	Feasibility of an Individualized Goals of Care Discussion Guide for Advanced Breast Cancer		Completed	No Results Available	Breast Cancer	Other: IGCDG	Recruitment rate|Attrition rate|Change in distress|Evaluate baseline preferences for care among patients with metastatic breast cancer via the Individualized Goals of Care Discussion Guide (IGCDG) questionnaire|The Satisfaction with Decision Making Scale|The Decisional Conflict Scale|Modified Control Preferences Scale|Patient Satisfaction with Cancer Care	Massachusetts General Hospital|Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	45	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	17-398	January 22, 2018	April 29, 2019	April 29, 2019	December 18, 2017		March 14, 2023	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03375827
8	NCT02956473	Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy		Completed	No Results Available	Breast Cancer	Device: Supine MRI|Other: Neoadjuvant Therapy (NAT)|Device: Ultrasound|Device: Mammography|Procedure: Standard of Care	Evaluate The Correlation Between Prone Breast MRI in Estimating Tumor Size at upfront surgery or post-NAT and Pathologic Results, and The Correlation Between Supine Breast MRI And Pathologic Results.|Compare The Correlation Between Supine Breast MRI for Estimation Of Tumor Size at upfront surgery or post-NAT and The Pathologic Residual Tumor Size, and The Correlation Between Existing Breast Imaging Modalities And The Pathologic Residual Tumor Size.|Characterize The Changes Occurring In Breast Tumor-Associated Properties/ Dimensions Between The Prone And Supine Imaging Position And To Determine The Correlation Of Tumor Location And Geometry On supine MRI with prone MRI|Assess The Value Of Supine MRI For Radiologists Performing Second Look US Examinations/ Biopsies Following Identification Of New Lesions on MRI, And Performing Preoperative Lesion Localization Using Supine MRI Guidance|Assess The Perceived Benefit Of Supine MRI For Surgical Planning As Measured By The Collective Results Of A Survey Of Surgeons Performing Breast-conserving Therapy (BCT) In Our Study Patient Population|Explore The Effect Of Supine MRI On Influencing Breast-conserving Surgery (BCS) Outcomes|Assess The Perceived Value Of Supine MRI For Adjuvant Radiation Breast Treatment Planning	Dana-Farber Cancer Institute	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	57	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	16-277	November 15, 2016	August 2022	August 2022	November 6, 2016		August 17, 2022	Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02956473
9	NCT03316586	A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer		Completed	Has Results	Breast Cancer	Drug: Nivolumab|Drug: Cabozantinib	Overall Response Rate|Number of Participants With Adverse Events|Clinical Benefit Rate|Progression Free Survival Rate|Overall Response Rate Per Immune Criteria	Dana-Farber Cancer Institute|Bristol-Myers Squibb|Exelixis	Female	18 Years and older   (Adult, Older Adult)	Phase 2	18	Other|Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-324	November 30, 2017	August 30, 2019	August 30, 2019	October 20, 2017	December 28, 2021	December 28, 2021	Dana-Farber Cancer Institute, Boston, Massachusetts, United States	"Study Protocol and Statistical Analysis Plan", https://clinicaltrials.gov/ProvidedDocs/86/NCT03316586/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03316586
10	NCT02663973	Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III		Completed	No Results Available	Breast Cancer		Description of the epidemiology of breast cancer in the Brazilian population|Description of the socioeconomical characteristics of the Brazilian population with breast cancer|Characterization of the immunophenotypic markers of the tumor|Classification of breast cancer staging|Description of screening tests of breast cancer patients in Brazil|Main symptoms presented by patients with breast cancer in Brazil|Initial treatment for breast cancer of Brazilian patients|Type of palliative treatment for metastasis or recurrent breast cancer in Brazilian patients|Clinical outcome of Brazilian breast cancer patients|Types of clinical complications displayed by breast cancer Brazilian patients|Characterization of exterior factors that may impact clinical outcome of breast cancer Brazilian patients	Latin American Cooperative Oncology Group|Ministry of Health, Brazil|Avon Institute	Female	18 Years and older   (Adult, Older Adult)		3000	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	GBECAM 0115	January 1, 2016	June 15, 2020	April 1, 2021	January 26, 2016		June 15, 2021	Clínica AMO, Salvador, Bahia, Brazil|Núcleo de Oncologia da Bahia, Salvador, Bahia, Brazil|Centro Regional Integrado de Oncologia (CRIO), Fortaleza, Ceará, Brazil|Centro de Pesquisa do Setor de Ginecologia e Mama do Hospital Araújo Jorge, Goiânia, Goiás, Brazil|Unidade de Pesquisa Clínica/Hospital de Clínicas da UFG, Goiânia, Goiás, Brazil|Unidade de Pesquisa Clínica do Hospital do Câncer de Londrina, Londrina, Paraná, Brazil|Hospital Jardim Amália, Volta Redonda, Rio De Janeiro, Brazil|Centro de Pesquisa Clínica da Liga Norte Riograndense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil|Centro de Pesquisas da Serra Gaúcha, Caxias do Sul, Rio Grande Do Sul, Brazil|Instituto de Pesquisa Clínicas para Estudos Multicêntricos da UCS, Caxias do Sul, Rio Grande Do Sul, Brazil|Hospital da Cidade de Passo Fundo - Clínica CITO, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Grupo de Estudos em Pesquisa de Pelotas, Pelotas, Rio Grande Do Sul, Brazil|CPO - Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Novos Tratamentos em Câncer - Hospital Santa Casa de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|CEPON, Florianópolis, Santa Catarina, Brazil|Clínica de Neoplasias Litoral - Centro de Novos Tratamentos Itajaí, Itajaí, Santa Catarina, Brazil|Instituto Oncológico de Ribeirão Preto - InORP, Ribeirão Preto, São Paulo, Brazil|Instituto Nacional do Câncer, Rio de Janeiro, Brazil|Oncoclínica, Rio de Janeiro, Brazil|Centro de Pesquisa Clínica do Hospital Israelita Albert Einstein, São Paulo, Brazil|Centro de Pesquisa Instituto do Câncer Arnaldo Vieira de Carvalho, São Paulo, Brazil|Hospital AC Camargo, São Paulo, Brazil		https://ClinicalTrials.gov/show/NCT02663973
11	NCT03021031	Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Clinical Core		Enrolling by invitation	No Results Available	Parkinson Disease	Other: Observational	Registry	University of Minnesota	All	21 Years and older   (Adult, Older Adult)		60	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	NEURO-2016-25066	September 19, 2017	July 1, 2026	January 2027	January 13, 2017		May 3, 2023	University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT03021031
12	NCT04431700	Study of Dietary Composition in Crohn's Disease	CD	Recruiting	No Results Available	Inflammatory Bowel Diseases|Crohn Disease	Other: Anti-inflammatory diet|Other: Regular diet	Efficacy of the anti-inflammatory whole food diet for the induction of remission in Crohn's Disease	University of California, Los Angeles	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	116	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	20-001120	October 5, 2020	January 31, 2025	May 1, 2025	June 16, 2020		May 6, 2023	UCLA Center for Human Nutrition, 1000 Veteran Ave., Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT04431700
13	NCT01767818	Parkinson's Disease Biomarker Program	PDBP	Completed	No Results Available	Parkinson's Disease		To estimate the mean rates of change and the variability around the mean of clinical outcomes in PD patients over 3-5 years of follow-up comparing these rates between PD patients of each stage of the Hoehn and Yahr.|To determine the predictive value of iTUG/iSWAY test results on future course of the disease	University of Texas Southwestern Medical Center|National Institute of Neurological Disorders and Stroke (NINDS)	All	30 Years and older   (Adult, Older Adult)		238	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	NS-12-011|1U01NS082148-01	November 2012	September 30, 2017	September 30, 2017	January 14, 2013		May 7, 2018	UT Southwestern Medical Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT01767818
14	NCT05103280	Improving Walking in Peripheral Artery Disease	PAD	Recruiting	No Results Available	Peripheral Artery Disease	Other: Assistive tennis shoes	Changes in walking distance after three-months intervention|Comfort level of wearing assistive shoe expressed as a numeric value and this value will be rated by participants|Changes in vertical ground reaction force after three-months intervention|Changes in muscle oxygenation after three-months intervention|Changes in physical activity after three-months intervention|Changes in Walking Impairment Questionnaire score after three-months intervention	VA Office of Research and Development|University of Nebraska	All	40 Years and older   (Adult, Older Adult)	Not Applicable	20	U.S. Fed|Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	F3877-P|I21RX003877	October 1, 2021	September 30, 2023	September 30, 2023	November 2, 2021		November 15, 2022	Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska, United States		https://ClinicalTrials.gov/show/NCT05103280
15	NCT03078192	Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging	XenonMRI	Completed	Has Results	Pulmonary Vascular Disease	Drug: GE-141, Hyperpolarized 129Xenon gas|Device: MRI	Participants Determined to be True Positives for Pulmonary Arterial Hypertension	Bastiaan Driehuys|National Heart, Lung, and Blood Institute (NHLBI)|Duke University	All	18 Years and older   (Adult, Older Adult)	Phase 2	62	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	Pro00079617|HHSN268201700001C	May 3, 2017	October 22, 2020	October 22, 2020	March 13, 2017	February 22, 2022	February 22, 2022	Duke University Medical Center, Durham, North Carolina, United States	"Study Protocol and Statistical Analysis Plan", https://classic.clinicaltrials.gov/ProvidedDocs/92/NCT03078192/Prot_SAP_000.pdf|"Informed Consent Form", https://classic.clinicaltrials.gov/ProvidedDocs/92/NCT03078192/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT03078192
16	NCT00695591	Home Sleep Testing in Neuromuscular Disease Patients	HSTNMD	Completed	No Results Available	Neuromuscular Disease	Other: Evaluation for Nocturnal non invasive ventilation	1. End tidal CO2 catheter is tolerated for six hours or more|1. Interpretable data are captured for oximetry, heart rate, and end-tidal CO2|2. An interpretive report is generated that will guide the non-pulmonary physician in potential interventions|2. Patients and parents are able to apply the monitors at home and a six hour data set is collected	Landon Pediatric Foundation	All	8 Years to 50 Years   (Child, Adult)		9	Other	Observational	Observational Model: Case-Only|Time Perspective: Prospective	LS01	July 2008	September 2008	July 2009	June 12, 2008		August 13, 2014	Pediatric Diagnostic Center, Ventura, California, United States		https://ClinicalTrials.gov/show/NCT00695591
17	NCT00513903	Expanding the Role of Pharmacists in Treating Persons With Cardiovascular or Lung Diseases	IowaCOC	Completed	No Results Available	Cardiovascular Diseases|Lung Diseases	Behavioral: Minimal intervention|Behavioral: Enhanced Intervention	ADEs|Medication appropriateness|Complications related to medications, including the number of hospital readmissions, unscheduled visits to emergency departments or urgent care facilities, and physician visits related to a medication problem or ADE|Cost-effectiveness of the minimal or enhanced treatment compared to usual care|Number of medications|Complete medication list|Community physician and pharmacist surveys|Medication adherence|Barriers to patient adherence	University of Iowa|National Heart, Lung, and Blood Institute (NHLBI)	All	18 Years and older   (Adult, Older Adult)	Phase 3	954	Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	498|R01HL082711|R01HL082711-01A2	March 2008	July 2012	October 2012	August 9, 2007		August 19, 2014	The University of Iowa, Iowa City, Iowa, United States		https://ClinicalTrials.gov/show/NCT00513903
18	NCT02709148	State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With Deep Brain Stimulation (DBS)		Completed	No Results Available	Parkinson's Disease	Device: Activa PC+S	Cortical and sub-cortical brain signals using Activa PC+S	University of Minnesota	All	45 Years to 75 Years   (Adult, Older Adult)	Phase 1	1	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	NEURO-2016-24512	July 20, 2017	July 31, 2019	July 31, 2020	March 15, 2016		January 13, 2021	University of Minnesota, Minneapolis, Minnesota, United States		https://ClinicalTrials.gov/show/NCT02709148
19	NCT04515550	Mitochondrial Biomarkers in Huntington's Disease		Completed	No Results Available	Huntington Disease	Diagnostic Test: lumbar puncture	Change in Unified Huntington Disease Rating Scale (UHDRS) and UHDRS sub-sections|Change in Montreal Cognitive Assessment (MoCA)	University Hospitals Cleveland Medical Center|Case Western Reserve University|National Institute of Neurological Disorders and Stroke (NINDS)|The Cleveland Clinic	All	20 Years to 85 Years   (Adult, Older Adult)		27	Other|NIH	Observational	Observational Model: Cohort|Time Perspective: Prospective	20181082|1R21NS107897-01A1	April 4, 2019	February 28, 2022	February 28, 2022	August 17, 2020		April 12, 2022	University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT04515550
20	NCT01659762	A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.	EPIC/MSC/IBD	Completed	No Results Available	Crohn's Disease	Biological: autologous mesenchymal stromal cell	Number of adverse events|Crohn's disease activity Index (CDAI)	Emory University|Atlanta Clinical and Translational Science Institute	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1	16	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00051454|EPIC001	July 2012	July 2015		August 8, 2012		October 17, 2016	Emory University, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT01659762
21	NCT01001585	Anesthetic Effects in Mitochondrial Disease		Terminated	No Results Available	Mitochondrial Disease	Drug: sevoflurane	Measure cardiovascular stability and electrical brain activity during slow induction with sevoflurane.|Use cardiovascular and electrical brain measurements to limit amount of sevoflurane and predict individual sensitivity.	d sessler|The Cleveland Clinic	All	12 Months to 16 Years   (Child)	Not Applicable	55	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Supportive Care	06-644	September 2006	September 2011	October 2011	October 26, 2009		March 9, 2015	Cleveland Clinic, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT01001585
22	NCT02134795	A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease		Completed	No Results Available	Parkinson's Disease	Device: TNM (trade name), a form of brainstem Stimulation	Motor UPDRS score (Unified Parkinson's Disease Rating Scale)|EKG to record beat-to-beat (R-R) interval data	Scion NeuroStim	All	18 Years and older   (Adult, Older Adult)	Not Applicable	6	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SNS-PD-01	May 2014	September 2014	September 2014	May 9, 2014		December 22, 2016	Duke University Health System, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02134795
23	NCT03190837	A Long-term Follow-up Study of Gaucher Disease		Recruiting	No Results Available	Gaucher Disease		Document effects of Gaucher disease in different systems of body, including nervous system, liver, and spleen.|Document adverse events subjects experience on enzyme replacement therapy|Document adverse events of subjects on substrate reduction therapy|Document long-term complications in Gaucher Disease.|Change in 36-Item Short Form Survey (SF-36) collected every 6 months/1 year.|Change in Small Fiber Neuropathy Screening List (SFNSL) collected every 6 months/1 year.|Document number of subjects experiencing neurological symptoms related to Gaucher, by using Neurological Follow-up exam|Change in Parkinson's checklist collected every 6 months/1 year.	Duke University	All	Child, Adult, Older Adult		200	Other	Observational	Observational Model: Other|Time Perspective: Prospective	Pro00081246	June 12, 2017	January 2027	January 2027	June 19, 2017		October 10, 2022	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03190837
24	NCT00320151	Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases		Completed	No Results Available	Pulmonary Diseases			Weill Medical College of Cornell University	All	18 Years to 90 Years   (Adult, Older Adult)		3087	Other	Observational	Observational Model: Other|Time Perspective: Other	Blood Collection Protocol	April 2006	August 2015	August 2015	May 3, 2006		May 24, 2017	Weill Medical College of Cornell University, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00320151
25	NCT02717442	Study of OTO-104 in Subjects With Unilateral Meniere's Disease	AVERTS-2	Terminated	Has Results	Meniere's Disease	Drug: OTO-104|Drug: Placebo	The Number of DVD at Week 12 (the 4-week [28 Days] Interval From Week 9 Through Week 12) - FAS-1 Population|The Number of DVD at Week 12 (the 4-week [28 Days] Interval From Week 9 Through Week 12) - FAS-2 Population|Effect of Vertigo on Daily Activities - Number of Days Sick at Home or Bedridden at Week 12 (Month 3): FAS-1|Effect of Vertigo on Daily Activities - Number of Days Sick at Home or Bedridden at Week 12 (Month 3): FAS-2|Otoscopic Examination - Tympanic Membrane Perforation at Week 12 (Month 3)|Audiometry - Shift in Air-Bone Gap at 500 Hz From Baseline to Week 12 (Month 3)|Audiometry - Shift in Air-Bone Gap at 1000 Hz From Baseline to Week 12 (Month 3)|Audiometry - Shift in Air-Bone Gap at 2000 Hz From Baseline to Week 12 (Month 3)	Otonomy, Inc.	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 3	176	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	104-201508	March 21, 2016	August 31, 2017	September 15, 2017	March 23, 2016	January 13, 2023	January 13, 2023	Many sites in Europe. Refer to the contact info listed below., San Diego, California, United States	"Study Protocol and Statistical Analysis Plan", https://classic.clinicaltrials.gov/ProvidedDocs/42/NCT02717442/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02717442
26	NCT03811496	Biomarker Analysis for GBA Associated Parkinson's Disease		Unknown status	No Results Available	Parkinson Disease|Gaucher Disease		Gene expression levels of SNCA|Gene expression levels of LRRK2|Gene expression levels of Parkin|Protein expression levels of alpha-synuclein|Protein expression levels of LRRK2|Protein expression levels of Parkin	Lysosomal and Rare Disorders Research and Treatment Center, Inc.	All	50 Years and older   (Adult, Older Adult)		100	Other	Observational	Observational Model: Cohort|Time Perspective: Prospective	18-LDRTC-01	February 1, 2018	February 2020	July 2020	January 22, 2019		January 23, 2019	LDRTC, Fairfax, Virginia, United States		https://ClinicalTrials.gov/show/NCT03811496
27	NCT02548897	Uncovering an Electrical Biomarker for Freezing of Gait in Parkinson's Disease		Completed	No Results Available	Parkinson's Disease	Device: Deep brain stimulation|Other: Electroencephalography	Number of freezing of gait events	University of Florida	All	30 Years to 75 Years   (Adult, Older Adult)	Not Applicable	5	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	IRB201500458	October 2015	August 15, 2017	August 15, 2017	September 14, 2015		September 25, 2017	University of Florida, Gainesville, Florida, United States		https://ClinicalTrials.gov/show/NCT02548897
28	NCT02612337	Study of OTO-104 in Subjects With Unilateral Meniere's Disease	AVERTS-1	Completed	Has Results	Meniere's Disease	Drug: OTO-104|Drug: Placebo	The Number of DVD at Week 12 (Defined as the 4-week [28 Days] Interval From Week 9 Through Week 12).|Effect of Vertigo on Daily Activities - Number of Days Sick at Home or Bedridden at Week 12 (Month 3)|Otoscopic Examination - Tympanic Membrane Perforation at Week 12 (Month 3)|Audiometry - Shift in Air-Bone Gap at 500 Hz From Baseline to Week 12 (Month 3)|Audiometry - Shift in Air-Bone Gap at 1000 Hz From Baseline to Week 12 (Month 3)|Audiometry - Shift in Air-Bone Gap at 2000 Hz From Baseline to Week 12 (Month 3)	Otonomy, Inc.	All	18 Years to 85 Years   (Adult, Older Adult)	Phase 3	166	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	104-201506	October 27, 2015	July 18, 2017	July 18, 2017	November 23, 2015	January 12, 2023	January 12, 2023	Many sites in US. Refer to the contact info listed below., San Diego, California, United States	"Study Protocol and Statistical Analysis Plan", https://classic.clinicaltrials.gov/ProvidedDocs/37/NCT02612337/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02612337
29	NCT04930666	BREATHE ALD: A Shared Decision-Making Intervention for Adults With Advanced Lung Disease	BREATHE-ALD	Recruiting	No Results Available	Pulmonary Disease, Chronic Obstructive|Lung Diseases, Interstitial	Other: BRief intervention to Enhance Adherence to Treatment and HEalth advice in Advanced Lung Disease	Number of qualitative interviews completed in the development phase|Ratio of participants who completed the intervention to the number of participants consented|Mean mMRC (Modified Medical Research Council) Dyspnea Scale|Mean St. George's Respiratory Questionnaire|Mean PROMIS Pain Intensity - Short Form V10 3a|Mean PROMIS Fatigue - Short Form 6a|Mean Short Form 36|Mean Shared Decision Making Questionnaire	Columbia University|Weill Medical College of Cornell University|National Institute of Nursing Research (NINR)	All	18 Years and older   (Adult, Older Adult)		60	Other|NIH	Observational	Observational Model: Other|Time Perspective: Cross-Sectional	AAAT2217|P20NR018072	November 10, 2021	December 2023	December 2023	June 18, 2021		April 14, 2023	Weill Cornell Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04930666
30	NCT02975193	Neural Correlates of Cognition in Parkinson's Disease		Completed	No Results Available	Parkinson Disease	Behavioral: Computer task assessing cognition|Behavioral: Impulsive-Compulsive Disorders in Parkinson's Disease|Procedure: Deep Brain Stimulation Surgery	Change in behavioral performance|Change in Score on Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)|Local field potential brain signal	University of Florida|National Institute of Neurological Disorders and Stroke (NINDS)	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	64	Other|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	IRB201601780|F30NS111841	February 1, 2017	October 25, 2020	October 25, 2020	November 29, 2016		February 15, 2021	University of Florida, Gainesville, Florida, United States		https://ClinicalTrials.gov/show/NCT02975193
31	NCT05218850	The Use of Butyrate Therapy in Pediatric Ulcerative Colitis		Not yet recruiting	No Results Available	Ulcerative Colitis	Drug: Butyrate	remission of clinical disease|calprotectin	Children's Hospital Los Angeles	All	7 Years to 21 Years   (Child, Adult)	Phase 1	10	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APP-22-00210	July 1, 2022	June 30, 2027	June 30, 2027	February 1, 2022		February 15, 2022	Children's Hospital Los Angeles, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT05218850
32	NCT05737836	Analyzing the Factors in Ulcerative Colitis Patients' Clinical Trial Experiences		Not yet recruiting	No Results Available	Ulcerative Colitis		Rate of patients who decide to join in an Ulcerative Colitis clinical trial|Number of Ulcerative Colitis patients who remain in clinical trial until completion	Power Life Sciences Inc.	All	18 Years and older   (Adult, Older Adult)		500	Industry	Observational	Observational Model: Case-Crossover|Time Perspective: Prospective	80979547	March 2024	March 2025	March 2026	February 21, 2023		June 12, 2023		"Informed Consent Form", https://classic.clinicaltrials.gov/ProvidedDocs/36/NCT05737836/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT05737836
33	NCT05430412	CT to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis		Recruiting	No Results Available	Ulcerative Colitis	Device: Adacolumn	Primary objective:evaluate if Adacolumn® can sustain clinical response to IFX for 12 weeks of follow-up (V.11) or 40 weeks of follow-up (V18). Clinical response to IFX will be evaluated through PUCAI SCORE|Primary objective: evaluate if Adacolumn® can sustain clinical response to IFX for 12 weeks of follow-up (V.11) or 40 weeks of follow-up (V18). Clinical response to IFX will be evaluated through IFX-LEVELS|Primary objective:evaluate if Adacolumn® can sustain clinical response to IFX for 12 weeks of follow-up (V.11) or 40 weeks of follow-up (V18). Clinical response to IFX will be evaluated through STEROIDS USE|To evaluate the IFX and ATI level variations in the treatment regimen during the study period. Quantification of IFX trough and ATI levels, and description of the IFX dose at baseline, 12 and 40 weeks of follow-up|To measure the PUCAI score variation during the study period. Measurement of PUCAI score at baseline, 12 and 40 weeks of follow-up.|To determine the percentage of patients maintaining steroid-free response during the study period at 12 and 40 weeks.|To describe the number of flare-ups during the study period. Patients experiencing flares-ups during the study period.|To measure faecal calprotectin level during the study period. Quantification of faecal calprotectin level at baseline, 12 and 40 weeks of follow-up. Faecal calprotectin is associated with clinical remission with levels higher than 150 μg/g.|To monitor the evolution of biochemical markers of inflammatory activity in UC and other laboratory parameters. Measurement of C-reactive protein, ESR, haemoglobin, albumin, platelet levels, PT, granulocytes at baseline, 12(V11) and 40 weeks(V18)|To determine the evolution of leucocyte counts in peripheral blood during the study period. Quantification of leucocyte counts in peripheral blood at baseline, 12 and 40 weeks of follow-up.|To evaluate the safety of Adacolumn® during the study period, all the recorded AEs will be described by:	Adacyte Therapeutics SL|Adknoma Health Research	All	up to 18 Years   (Child, Adult)	Not Applicable	15	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GUITAR	January 11, 2022	June 2023	September 2023	June 24, 2022		June 24, 2022	Hospital Coimbra, Coimbra, Portugal|Hospital Santa Maria, Lisboa, Portugal|Hospital Soa Joao, Oporto, Portugal|Hospital H. Sant Joan de Déu, Sant Joan Despí, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Hospital Materno-Infantil del H.U.R. de Málaga, Málaga, Spain|Complejo H. Regional Virgen Del Rocío, Sevilla, Spain|Hospital U. Ntra Señora de Candelaria, Tenerife, Spain|Hospital Universitari I Politècnic La Fe, Valencia, Spain		https://ClinicalTrials.gov/show/NCT05430412
34	NCT03986996	Antimicrobial Therapy for Ulcerative Colitis (UC)	UC	Terminated	No Results Available	Ulcerative Colitis	Drug: amoxicillin, metronidazole and doxycycline|Drug: amoxicillin and doxycyclin	Efficacy - Clinical Response in group 1 and 2 or Clinical Remission|Efficacy - Clinical Response in group 1 and 2|EFFICACY - Remission|EFFICACY - PGA|EFFICACY - Corticosteroid free remission|EFFICACY - Decrease in endoscopic disease activity	Wolfson Medical Center	All	13 Years to 60 Years   (Child, Adult)	Phase 2	20	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	AntimicrobialUC	July 25, 2019	May 29, 2022	May 30, 2022	June 14, 2019		June 1, 2022	The E.Wolfson Medical Center, Holon, Israel		https://ClinicalTrials.gov/show/NCT03986996
35	NCT05679622	Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis (UC)	FMT	Recruiting	No Results Available	Ulcerative Colitis	Other: Fecal Microbiota Transplantation	clinical response|clinical remission|safety of FMT|Number of patients requiring escalation of medical therapies|Number of patients with endoscopic remission|Fecal calprotectin level|C-reactive protein levels|erythrocyte sedimentation rate (ESR) level|The number of stools or bloody stools|gut microbial	Biao Zou|Tongji Hospital	All	2 Years to 16 Years   (Child)	Not Applicable	30	Other	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	63639979	December 1, 2022	June 30, 2025	June 30, 2025	January 11, 2023		February 8, 2023	Tongji Hospital, Wuhan, China		https://ClinicalTrials.gov/show/NCT05679622
36	NCT05084261	An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)	SCOUT	Completed	No Results Available	Ulcerative Colitis	Drug: BT051 200 mg|Drug: BT051 800 mg|Drug: BT051 3200 mg|Drug: Matching Placebo	Evaluate the safety and tolerability of BT051 based on the difference of proportions between treatment groups of subjects experiencing treatment-emergent adverse events (TEAEs)|Evaluate the safety and tolerability of BT051 based on the difference of proportions between treatment groups of subjects observed with a change from baseline in physical examinations, clinical laboratory tests, vital signs, and electrocardiograms (ECG)|Clinical response defined as a decrease in complete Mayo Score ≥3 points and ≥30% from baseline with a concomitant decrease in rectal bleeding subscore ≥1 point or absolute rectal bleeding subscore ≤1 point|Clinical response defined as a decrease in complete Mayo Score ≥2 points and ≥30% from baseline with a concomitant decrease in rectal bleeding subscore ≥1 point or absolute rectal bleeding subscore ≤1|Remission defined as a complete Mayo Score ≤2 points with no subscore >1 point at Day 28|Remission defined as a partial Mayo Score ≤2 points with no subscore >1 point at Days 14 and 28|Remission according to the adapted Mayo Score without the physician's global assessment, defined as a stool frequency subscore ≤1 point, rectal bleeding subscore of 0, and endoscopic subscore ≤1 point|Change in Mayo endoscopic, stool frequency, and rectal bleeding subscores.|Change in stool frequency and rectal bleeding Mayo subscores|Endoscopic remission defined as an Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score of 0|Endoscopic response defined as a decrease in UCEIS ≥2 points|Histologic remission defined as Geboes Score ≤2B.0 or Nancy Index = 0|Change in Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score|Change in Robarts histopathology index (RHI) score|Change in UC-100 score	Adiso Therapeutics	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1	24	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BT051-1-002	November 30, 2021	November 30, 2022	November 30, 2022	October 19, 2021		December 15, 2022	Inland Empire Clinical Trials, LLC, Rialto, California, United States|I.H.S. Health, LLC, Kissimmee, Florida, United States|Research Institute of Clinical Medicine Todua Clinic, Tbilisi, Georgia|Republican Clinical Hospital - Timofei Mosneaga, Chisinau, Moldova, Republic of|WIP Warsaw IBD Point, Warszawa, Poland|PlanetMed Gastroenterology, Wrocław, Poland		https://ClinicalTrials.gov/show/NCT05084261
37	NCT05867329	A Trial for Acute Severe Ulcerative Colitis		Not yet recruiting	No Results Available	Ulcerative Colitis Acute	Drug: Cyclosporine Injection (IV)|Drug: Cyclosporine Oral Product|Drug: Upadacitinib Extended Release Oral Tablet|Drug: Intravenous Methylprednisolone|Drug: Prednisone Oral Product	Proportion of randomly allocated participants to first stage of intervention|Proportion of randomly assigned participants that completed intervention and follow-up period up to 100 days|Proportion of participants with completed C-Reactive Protein (CRP) and daily bowel movements recorded prior to sequentially randomized allocation|Proportion of enrolled patients that successfully underwent the second randomization (or transition to the second-stage among participants not re-randomized)|Proportion of patients reporting trial design acceptable|Proportion of inpatient physicians reporting trial design acceptable|Proportion of patients undergoing same-admission colectomy|Proportion of patients undergoing colectomy within follow-up|Incidence and severity of adverse events|Proportion of patients in steroid-free remission at 90 days	Berinstein, Jeffrey|University of Michigan	Female	18 Years to 75 Years   (Adult, Older Adult)	Phase 4	162	Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HUM00228245	August 2023	May 2026	May 2026	May 22, 2023		June 23, 2023	University of Michigan, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT05867329
38	NCT05030064	Clinical Study on the Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis With Depression		Recruiting	No Results Available	Ulcerative Colitis	Drug: Intestinal flora capsule|Procedure: placebo capsule	PHQ-9 score|SDS-score|HAMA-score|HAMD-score|HADS-score|GSRS-score|Modified Mayo score|IBD-QoL	Third Military Medical University	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	54	Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TMMU-DP-GI-FMT-003	September 10, 2021	December 31, 2021	August 31, 2022	September 1, 2021		September 1, 2021	Department of Gastroenterology, Research Institute of Surgery, Da ping Hospital, The Third Military Medical University, Chongqing, Chongqing, China		https://ClinicalTrials.gov/show/NCT05030064
39	NCT03849599	A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis	PULSE	Completed	No Results Available	Ulcerative Colitis	Biological: PRV-300|Biological: Placebo	Incidence of Treatment-emergent adverse events (TEAEs),	Provention Bio, Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 1	37	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	PRV-300-UC1b	February 21, 2018	March 1, 2019	March 1, 2019	February 21, 2019		February 13, 2020	Clinical Site, Tbilisi, Georgia|Clinical Site, Chisinau, Moldova, Republic of|Clinical Site, Kapitanivka, Ukraine		https://ClinicalTrials.gov/show/NCT03849599
40	NCT05177835	Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis		Recruiting	No Results Available	Ulcerative Colitis	Drug: ABX464	Number of adverse events in ABX464 treated subjects|Percentage of subjects reaching clinical remission at yearly visits.|Percentage of subjects reaching endoscopic remission at yearly visits|Percentage of subjects reaching clinical response at yearly visits|Percentage of subjects reaching endoscopic improvement at yearly visits	Abivax S.A.	All	18 Years and older   (Adult, Older Adult)	Phase 2	203	Industry	Interventional	Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ABX464-108	December 3, 2021	February 2023	April 2026	January 5, 2022		January 19, 2022	UZ Leuven, Leuven, Belgium|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Nemocnice Slany, Slany, Czechia|DRC Gyogyszervizsgalo Kozpont Kft., Balatonfured, Hungary|Centrum Medyczne Plejady, Kraków, Poland|Trialmed CRS, Piotrkow Trybunalski, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Wroclaw, Poland|Samodzielny PZOZ w Lecznej, Łęczna, Poland		https://ClinicalTrials.gov/show/NCT05177835
